Close

Is AMR research ready to inform the next generation of global policy?

In this commentary, Prof Gwen Knight, Co-Director of the AMR Centre explores the evidence and modelling gaps that could shape global efforts to tackle antimicrobial resistance
Professor Gwen Knight, Co-Director, AMR centre

As the global antimicrobial resistance (AMR) community prepares for December's 5th Global High-Level Ministerial Conference on AMR in Abuja, Nigeria, attention is turning to the launch of the Independent Panel on Evidence for Action against Antimicrobial Resistance (IPEA).  
 
Established by the Quadripartite organisations (FAO, UNEP, WHO and WOAH), the panel aims to strengthen the generation and use of scientific evidence to support countries in tackling AMR. Its establishment comes at a critical time, as gaps in research, data and modelling continue to challenge evidence-informed policymaking [1].  

IPEA will focus on four key functions: assessing existing evidence, identifying emerging trends and risks, supporting access to policy-relevant evidence and tools, and encouraging knowledge sharing between researchers and policymakers [2]. 

Its work will be guided by an Expert Committee of 30 members, supported by thematic working groups. Through annual public calls, researchers, institutions and other stakeholders will be able to propose topics for consideration, helping shape the panel's priorities and work programme 

A central challenge for IPEA will be identifying where evidence already exists and where important gaps remain. Much of this work is likely to depend on evidence synthesis and mathematical modelling [3]. While systematic reviews can bring together existing findings, the underlying evidence for many AMR interventions remains limited, particularly across different settings. 

Mathematical models can help policymakers compare interventions, but their reliability depends on the quality of the data and assumptions used. A 2019 review found that only 43% of population-level AMR models were calibrated to epidemiological data, while just 14% were validated using independent data [4]. A 2025 review found little improvement, with 41% of models calibrated and persistent gaps in geographical coverage and drug–pathogen combinations [5]. 

These limitations matter because AMR interventions are not equally applicable across pathogens or settings. Effective prioritisation must consider differences in disease transmission, available interventions and their potential impacts across human, animal and environmental health [6]. It must also account for the range of outcomes that interventions may produce, as highlighted by the IMPACT-AMR network. 

While global estimates of antibiotic use are improving [8], important questions remain about how antibiotic use relates to resistance across different pathogens and populations. Understanding these relationships is essential for evaluating interventions designed to reduce antibiotic use and, ultimately, resistance. IPEA can only assemble the jigsaw from pieces that already exist, and for AMR research, many are still to be made. 

The good news is that researchers have opportunities to shape the panel's work, including applying to its Expert Committee and working groups, proposing topics through annual public calls and commenting on its draft work programme. 

The challenge now is for the AMR research community to work together, identify the evidence and modelling tools already available, address critical gaps and be ready to respond when IPEA comes calling. 

Have your say: Help shape IPEA’s research priorities 

The Global Strategy Lab, together with INAMRSS and IMPACT-AMR, is inviting researchers and professionals working across AMR disciplines to help identify the scientific priorities IPEA should address in its first two years and beyond. 

The survey takes approximately 15 minutes to complete and is open until 20 November 2026 

Take part in the survey 

For further information, explore IPEA’s founding documents. 
 

 

References 

[1] United Nations General Assembly. Political Declaration of the High-level Meeting on Antimicrobial Resistance. A/RES/79/2, 2024. 

[2] Quadripartite Joint Secretariat on AMR. Terms of Reference: Independent Panel on Evidence for Action against Antimicrobial Resistance. 2026. 

[3] Boily-Larouche G, Ruckert A, Rohde H, Friedland J, Skov R, Wallace LJ, Poirier MJP, Sharland M. Design to Delivery: Structuring IPEA’s Scientific Work to Meet Policy Needs. GSL Policy Brief. Global Strategy Lab and ESCMID; November 2025. 

[4] Niewiadomska AM, Jayabalasingham B, Seidman JC, Willem L, Grenfell B, Spiro D, Viboud C. Population-level mathematical modeling of antimicrobial resistance: a systematic review. BMC Med. 2019 Apr 24;17(1):81. doi: 10.1186/s12916-019-1314-9. PMID: 31014341; PMCID: PMC6480522.  

[5] Brinch ML, Palladino A, Geurtsen J, Van Effelterre T, Argante L, McConnell MJ, Christiansen L, Pihl MA, Lund NK, Hald T. The neglected model validation of antimicrobial resistance transmission models – a systematic review. Antimicrob Resist Infect Control. 2025;14:59. doi: 10.1186/s13756-025-01574-x 

[6] Aluzaite K, Dione M, Belay D, Naylor NR, Chan D, Emes E, Guitian J, Robotham JV, Knight GM. Prioritising antimicrobial resistance interventions from a One Health perspective: lessons and applied tools for diverse contexts. Rev Sci Tech (WOAH Scientific and Technical Review). 2025;44. doi: 10.20506/rst.44.3685 

[8] Cook A, Cooper B, Thorn M, Nguyen N, Lim C, Swe MMM, Allel K, Robles Aguilar G, Moore CE, Lewnard JA, Cohn J, Mendelson M, Laxminarayan R, Srikantiah P, Pouwels KB, Sharland M. Estimating optimal levels of WHO Access, Watch, Reserve (AWaRe) antibiotic use in 186 countries, territories, and areas on the basis of clinical infection and resistance burden. Lancet Public Health. 2026 Aug;11(8):e476-e486. doi: 10.1016/S2468-2667(26)00103-9. PMID: 42480563. 

Study at LSHTM

If you enjoyed this article and would like to build a career in global health, we offer a range of MSc programmes covering health and data, infectious and tropical diseases, population health, and public health and policy. 

Available on campus or online, including flexible study that works around your work and home life, be part of a global community at the UK's no.1 public health university.